WHO

Greenway Products Available Online, Update on International Sales Accreditation

Retrieved on: 
Wednesday, March 27, 2024
WHO, Ontario Cannabis Retail Corporation, Sale, GACP, EMA, Drug

Greenway has begun the process of getting a CUMS-GAP certificate and GACP certified, accreditation standards that are required to sell into a multitude of countries around the globe.

Key Points: 
  • Greenway has begun the process of getting a CUMS-GAP certificate and GACP certified, accreditation standards that are required to sell into a multitude of countries around the globe.
  • "Our team is thrilled to see our MillRite Lavender Haze pre-rolls available for sale through the Ontario Cannabis Store.
  • "I am also happy to be able to give an update on our pursuit of expanding our wholesale cannabis sales to the international market," said Jamie D'Alimonte, CEO.
  • We have already begun the accreditation process, and have entered into conversation with a few different international cannabis purchasers as well as some of our already established domestic partners who have established international sales routes, in anticipation of completing the process."

Access to Nutrition Initiative study reveals that Food for infants and toddlers from leading brands fails to meet marketing and nutritional standards

Retrieved on: 
Tuesday, March 26, 2024
Mother, Health, Caregiver, Danone, Social media, Policy, Substitute, BMS, FHA insured loan, Infant, Code, Intake, Marketing, Hero, Safety, Access, WHO, Helen Keller International, ATNI, Parent, Dietary supplement

UTRECHT, The Netherlands, March 26, 2024 /PRNewswire/ -- The Access to Nutrition Initiative (ATNI) unveils three assessments showing inappropriate marketing and nutritional inadequacies of foods intended for infants and young children.

Key Points: 
  • UTRECHT, The Netherlands, March 26, 2024 /PRNewswire/ -- The Access to Nutrition Initiative (ATNI) unveils three assessments showing inappropriate marketing and nutritional inadequacies of foods intended for infants and young children.
  • None of the commercial complementary food products for infants and young children were found suitable for promotion for consumption by children aged 6 months to three years.
  • The first study shows only 35% meet all nutritional requirements, with 25-33% of products assessed containing excessive levels of sugar or inappropriate energy levels.
  • said Kathy Spahn, Board Member of the Access to Nutrition Initiative (ATNI) and former President and CEO, Helen Keller International.

Access to Nutrition Initiative study reveals that Food for infants and toddlers from leading brands fails to meet marketing and nutritional standards

Retrieved on: 
Tuesday, March 26, 2024
Mother, Health, Caregiver, Danone, Social media, Policy, Substitute, BMS, FHA insured loan, Infant, Code, Intake, Marketing, Hero, Safety, Access, WHO, Helen Keller International, ATNI, Parent, Dietary supplement

UTRECHT, The Netherlands, March 26, 2024 /PRNewswire/ -- The Access to Nutrition Initiative (ATNI) unveils three assessments showing inappropriate marketing and nutritional inadequacies of foods intended for infants and young children.

Key Points: 
  • UTRECHT, The Netherlands, March 26, 2024 /PRNewswire/ -- The Access to Nutrition Initiative (ATNI) unveils three assessments showing inappropriate marketing and nutritional inadequacies of foods intended for infants and young children.
  • None of the commercial complementary food products for infants and young children were found suitable for promotion for consumption by children aged 6 months to three years.
  • The first study shows only 35% meet all nutritional requirements, with 25-33% of products assessed containing excessive levels of sugar or inappropriate energy levels.
  • said Kathy Spahn, Board Member of the Access to Nutrition Initiative (ATNI) and former President and CEO, Helen Keller International.

Youth Health Priority: WHO's "Stop the Lies" Campaign Takes Aim at Tobacco Industry Tactics

Retrieved on: 
Monday, March 25, 2024
Temperature, Health, Culture, Tobacco industry, Communication, Lies, Public, Policy, News, Tobacco, Weapons in Star Trek, HTPS, Smoke, Nature, Good governance, Health policy, World Health Organization, Heated tobacco product, WHO, Public opinion

TAMPA BAY, Fla., March 25, 2024 /PRNewswire-PRWeb/ -- The World Health Organization (WHO)'s "Stop the Lies" campaign demonstrates a comprehensive and proactive approach to combating tobacco industry interference and protecting public health, particularly among young people. By leveraging evidence, amplifying youth voices, and advocating for policy protection, the campaign embodies WHO's commitment to advancing global health goals. "The WHO campaign was impressive, a real PR win over big tobacco," explains Karla Jo Helms, Anti-PR Chief Strategist of JOTO PR Disruptors. "It's a proactive strategy that changed minds."

Key Points: 
  • TAMPA BAY, Fla., March 25, 2024 /PRNewswire-PRWeb/ -- The World Health Organization (WHO)'s "Stop the Lies" campaign demonstrates a comprehensive and proactive approach to combating tobacco industry interference and protecting public health, particularly among young people.
  • By leveraging evidence, amplifying youth voices, and advocating for policy protection, the campaign embodies WHO's commitment to advancing global health goals.
  • "The WHO campaign was impressive, a real PR win over big tobacco," explains Karla Jo Helms, Anti-PR Chief Strategist of JOTO PR Disruptors .
  • - Karla Jo Helms
    Evidence from the latest The Global Tobacco Industry Interference Index 2023, published by STOP and the Global Center for Good Governance in Tobacco Control, supported WHO's campaign.

New PeerLINC Knowledge Hub will Leverage Local Expertise and Experience to Accelerate New, More Effective TB Cures Around the World

Retrieved on: 
Monday, March 25, 2024
Knowledge, Control, Moxifloxacin, Health, TDF, Government, Disease, Tuberculosis, Partnership, Trustee, Research, Linezolid, DOH, Senior, World Health Organization, Directorate, WHO, TB, Market access, Interim, NTRL, Molina Healthcare, TB Alliance, Miliary tuberculosis, Pharmaceutical industry

MANILA, Australia, March 24, 2024 /PRNewswire/ -- TB Alliance's new Peer-to-Peer Learning for Innovative Cures (PeerLINC) Knowledge Hub launched today in Manila, with funding from the Australian Government through the Partnerships for a Healthy Region initiative. PeerLINC, operating in partnership between TB Alliance and the Tropical Disease Foundation, Inc. (TDF), and in close collaboration with the Department of Health, Philippines, will help countries implement best practices in the treatment of drug-resistant tuberculosis (DR-TB) to help speed the worldwide programmatic implementation of innovative, more effective treatments for the disease, starting with the World Health Organization (WHO)-recommended six-month, all-oral BPaL/M regimens, composed of the antibiotics bedaquiline (B), pretomanid (Pa), and linezolid (L), with or without moxifloxacin (M).

Key Points: 
  • The Philippines has successfully and rapidly deployed new treatments through participation in TB Alliance's Leveraging Innovation for Faster TB Treatment ( LIFT-TB ) initiative.
  • "PeerLINC will make training and knowledge on new treatments available swiftly and efficiently to ensure their rapid adoption and roll out.
  • "Every country with drug-resistant TB can benefit from widespread implementation of the best available TB treatment.
  • The expert team from PeerLINC will continue to guide countries after trainings, as they work to implement the regimens.

New PeerLINC Knowledge Hub will Leverage Local Expertise and Experience to Accelerate New, More Effective TB Cures Around the World

Retrieved on: 
Monday, March 25, 2024
Knowledge, Control, Moxifloxacin, Health, TDF, Government, Disease, Tuberculosis, Partnership, Trustee, Research, Linezolid, DOH, Senior, World Health Organization, Directorate, WHO, TB, Market access, Interim, NTRL, Molina Healthcare, TB Alliance, Miliary tuberculosis, Pharmaceutical industry

MANILA, Australia, March 25, 2024 /PRNewswire/ -- TB Alliance's new Peer-to-Peer Learning for Innovative Cures (PeerLINC) Knowledge Hub launched today in Manila, with funding from the Australian Government through the Partnerships for a Healthy Region initiative. PeerLINC, operating in partnership between TB Alliance and the Tropical Disease Foundation, Inc. (TDF), and in close collaboration with the Department of Health, Philippines, will help countries implement best practices in the treatment of drug-resistant tuberculosis (DR-TB) to help speed the worldwide programmatic implementation of innovative, more effective treatments for the disease, starting with the World Health Organization (WHO)-recommended six-month, all-oral BPaL/M regimens, composed of the antibiotics bedaquiline (B), pretomanid (Pa), and linezolid (L), with or without moxifloxacin (M).

Key Points: 
  • The Philippines has successfully and rapidly deployed new treatments through participation in TB Alliance's Leveraging Innovation for Faster TB Treatment ( LIFT-TB ) initiative.
  • "PeerLINC will make training and knowledge on new treatments available swiftly and efficiently to ensure their rapid adoption and roll out.
  • "Every country with drug-resistant TB can benefit from widespread implementation of the best available TB treatment.
  • The expert team from PeerLINC will continue to guide countries after trainings, as they work to implement the regimens.

CGTN: China advances battle against tuberculosis

Retrieved on: 
Sunday, March 24, 2024
Diagnosis, Control, China Media Group, Disease, HIV/AIDS, Tuberculosis, World Tuberculosis Day, United, Patient, Research, United Nations, Hope, Volunteering, Health education, CDC, Vaccination, WHO, Media Group, TB, Parent, UN, Pharmaceutical industry

According to the World Health Organization's (WHO) Global Tuberculosis Report 2023, in 2022, there were more than 10.6 million cases of active TB globally, with 1.3 million deaths.

Key Points: 
  • According to the World Health Organization's (WHO) Global Tuberculosis Report 2023, in 2022, there were more than 10.6 million cases of active TB globally, with 1.3 million deaths.
  • The Chinese government attaches great importance to TB prevention and treatment and has incorporated it into the Healthy China strategy.
  • China also attaches great importance to the development of young volunteers and actively encourages public voluntary actions for TB prevention and control.
  • Over the past 10 years, the number of volunteers in China has increased to over 1 million, more than half of whom are young people.

CGTN: China advances battle against tuberculosis

Retrieved on: 
Sunday, March 24, 2024
Diagnosis, Control, China Media Group, Disease, HIV/AIDS, Tuberculosis, World Tuberculosis Day, United, Patient, Research, United Nations, Hope, Volunteering, Health education, CDC, Vaccination, WHO, Media Group, TB, Parent, UN, Pharmaceutical industry

According to the World Health Organization's (WHO) Global Tuberculosis Report 2023, in 2022, there were more than 10.6 million cases of active TB globally, with 1.3 million deaths.

Key Points: 
  • According to the World Health Organization's (WHO) Global Tuberculosis Report 2023, in 2022, there were more than 10.6 million cases of active TB globally, with 1.3 million deaths.
  • The Chinese government attaches great importance to TB prevention and treatment and has incorporated it into the Healthy China strategy.
  • China also attaches great importance to the development of young volunteers and actively encourages public voluntary actions for TB prevention and control.
  • Over the past 10 years, the number of volunteers in China has increased to over 1 million, more than half of whom are young people.

U.S. FDA Approves OPSYNVI® (macitentan and tadalafil) as the First and Only Once-Daily Single-Tablet Combination Therapy for Patients with Pulmonary Arterial Hypertension (PAH)

Retrieved on: 
Friday, March 22, 2024
Diagnosis, ESC, Toxicity, ERA, Tadalafil, Internal medicine, European Respiratory Society, Disease, Risk, Pulmonary hypertension, Patient, PVR, Mitigation, Female, Nitric oxide, Connective tissue disease, Orthostatic hypertension, World Health Organization, PDE5, Johnson & Johnson, REMS, WHO, Pulmonary circulation, PAH, FDA, Constriction, ERS, Food, Pharmaceutical industry

RARITAN, N.J., March 22, 2024  /PRNewswire/ -- Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) has approved OPSYNVI® – a single-tablet combination of macitentan, an endothelin receptor antagonist (ERA), and tadalafil, a phosphodiesterase 5 (PDE5) inhibitor – for the chronic treatment of adults with pulmonary arterial hypertension (PAH, World Health Organization [WHO] Group I) and WHO functional class (FC) II-III.1 OPSYNVI® may be used in patients with PAH who are treatment-naïve or who are already on an ERA, PDE5 inhibitor or both. OPSYNVI® may be used in patients who are currently treated concomitantly with stable doses of macitentan 10 mg and tadalafil 40 mg (20 mg x 2) as separate tablets.1

Key Points: 
  • Historically, this required patients to take multiple pills because no single-tablet combination therapy targeting two or more pathways was available," said Kelly Chin, M.D., Professor of Internal Medicine and Director of the Pulmonary Hypertension Program at UT Southwestern Medical Center, and an investigator in the A DUE study.
  • The FDA's approval of OPSYNVI® is based on the results from the pivotal Phase 3 A DUE study , in which OPSYNVI® demonstrated greater reduction in Pulmonary Vascular Resistance (PVR) after 16 weeks versus tadalafil or macitentan monotherapy.
  • "People with PAH often live with the burden of taking many pills each day, which can pose challenges," said James F. List, M.D., Ph.D., Global Therapeutic Area Head, whose team oversees a portfolio of programs including Pulmonary Hypertension at Johnson & Johnson.
  • "We're thrilled to bring this single-tablet combination therapy to patients, as it has the potential to optimize disease management and fulfill a significant unmet need in supporting recently updated treatment guidelines that call for initial or early combination treatment."

TELUS Mental Health Index: Workers under 40 in the US are isolated and lonely resulting in reduced mental health and productivity

Retrieved on: 
Tuesday, March 19, 2024
Health, Culture, Obesity, Trust, Social support, Mental health, Mortality, Social isolation, Organization, World Health Organization, Smoking, Housing, WHO, Workplace, Telus Health, Loneliness

Additionally, workers who don't feel valued and respected by their colleagues or supported by their workplace are twice as likely to report that their mental health adversely affects their productivity compared to workers who feel valued and respected.

Key Points: 
  • Additionally, workers who don't feel valued and respected by their colleagues or supported by their workplace are twice as likely to report that their mental health adversely affects their productivity compared to workers who feel valued and respected.
  • It also impacts businesses as loneliness and social isolation negatively impact both health and workplace productivity," said Paula Allen, Global Leader, Research & Client Insights, TELUS Health.
  • The TELUS Mental Health Index also found:
    Workers without trusted relationships are more likely to feel isolated, with 46 percent reporting feeling isolated compared to 14 percent of those with trusted relationships.
  • In January 2024, the mental health scores of workers in various regions were: